Officials at the FDA approved DermaSensor's software after analyzing the results of a study, led by the Mayo Clinic, that involved testing the device at 22 different clinics.
The results of the study showed that the device had a sensitivity of 96 percent and a specificity of 97 percent in detecting skin cancer cases. Additionally, a separate study demonstrated that the device helped reduce the rate of missed skin cancer cases from 18 percent to nine percent, as reported by 108 physicians using the device.
[
add
]
[
|
|
...
]